Primary treatment for oropharyngeal squamous cell carcinoma in Alberta, Canada: A population-based study

Amy J. Hobbs; Nigel T. Brockton; T. Wayne Matthews; Shamir P. Chandarana; Pinaki Bose; Kelly Guggisberg; Gordon H. Fick; Joseph C. Dort

doi:10.1002/hed.24889

Primary treatment for oropharyngeal squamous cell carcinoma in Alberta, Canada: A population-based study

Amy J. Hobbs, Nigel T. Brockton, T. Wayne Matthews, Shamir P. Chandarana, Pinaki Bose, Kelly Guggisberg, Gordon H. Fick, Joseph C. Dort

Bloomberg School of Public Health

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Background: The incidence of human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma (SCC) is increasing and has better survival than non-HPV related oropharyngeal SCC. This study compared surgical to nonsurgical treatments and demographic, clinical, and survival differences in patients with oropharyngeal SCC, stratified by p16 status. Methods: We assembled a cohort of adult patients with oropharyngeal SCC diagnosed between 2000 and 2008 in Alberta. The tumor p16 biomarker was measured using fluorescent immunohistochemistry. Results: In this cohort, p16 data were available for 115 of 357 patients; and 66% (n = 76) were p16-positive. Patients with p16 data had comparable outcomes to those without. Surgically treated p16-negative patients had improved 5-year disease-specific survival (DSS) and overall survival (OS) compared with nonsurgical patients. There were no differences in survival outcomes between surgical and nonsurgical treatment for patients with p16-positive disease. Conclusion: Patients with p16-positive oropharyngeal SCC had similar outcomes regardless of treatment. Patients with p16-negative tumors may benefit from primary surgery with postoperative adjuvant therapy.

Original language	English (US)
Pages (from-to)	2187-2199
Number of pages	13
Journal	Head and Neck
Volume	39
Issue number	11
DOIs	https://doi.org/10.1002/hed.24889
State	Published - Nov 2017

Keywords

chemoradiation
human papillomavirus
oropharyngeal squamous cell carcinoma
p16
surgery

ASJC Scopus subject areas

Otorhinolaryngology

Access to Document

10.1002/hed.24889

Cite this

@article{30d725bf3db84b9c936caf959836426c,

title = "Primary treatment for oropharyngeal squamous cell carcinoma in Alberta, Canada: A population-based study",

abstract = "Background: The incidence of human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma (SCC) is increasing and has better survival than non-HPV related oropharyngeal SCC. This study compared surgical to nonsurgical treatments and demographic, clinical, and survival differences in patients with oropharyngeal SCC, stratified by p16 status. Methods: We assembled a cohort of adult patients with oropharyngeal SCC diagnosed between 2000 and 2008 in Alberta. The tumor p16 biomarker was measured using fluorescent immunohistochemistry. Results: In this cohort, p16 data were available for 115 of 357 patients; and 66% (n = 76) were p16-positive. Patients with p16 data had comparable outcomes to those without. Surgically treated p16-negative patients had improved 5-year disease-specific survival (DSS) and overall survival (OS) compared with nonsurgical patients. There were no differences in survival outcomes between surgical and nonsurgical treatment for patients with p16-positive disease. Conclusion: Patients with p16-positive oropharyngeal SCC had similar outcomes regardless of treatment. Patients with p16-negative tumors may benefit from primary surgery with postoperative adjuvant therapy.",

keywords = "chemoradiation, human papillomavirus, oropharyngeal squamous cell carcinoma, p16, surgery",

author = "Hobbs, {Amy J.} and Brockton, {Nigel T.} and Matthews, {T. Wayne} and Chandarana, {Shamir P.} and Pinaki Bose and Kelly Guggisberg and Fick, {Gordon H.} and Dort, {Joseph C.}",

note = "Funding Information: This manuscript was completed as part of a Master of Science thesis in Clinical Epidemiology, Cumming School of Medicine, Department of Community Health Sciences, at the University of Calgary. Biomarker identification was conducted by the Functional Tissue Imaging Unit at the Tom Baker Cancer Centre Translational Research Laboratory and was funded by the Ohlson Research Initiative. A. J.H. received generous funding from an Alberta Innovates – Health Solutions Clinician Fellowship Award and from the Ohlson Research Initiative. Publisher Copyright: {\textcopyright} 2017 Wiley Periodicals, Inc.",

year = "2017",

month = nov,

doi = "10.1002/hed.24889",

language = "English (US)",

volume = "39",

pages = "2187--2199",

journal = "Head and Neck",

issn = "1043-3074",

publisher = "Wiley-Liss Inc.",

number = "11",

}

TY - JOUR

T1 - Primary treatment for oropharyngeal squamous cell carcinoma in Alberta, Canada

T2 - A population-based study

AU - Hobbs, Amy J.

AU - Brockton, Nigel T.

AU - Matthews, T. Wayne

AU - Chandarana, Shamir P.

AU - Bose, Pinaki

AU - Guggisberg, Kelly

AU - Fick, Gordon H.

AU - Dort, Joseph C.

N1 - Funding Information: This manuscript was completed as part of a Master of Science thesis in Clinical Epidemiology, Cumming School of Medicine, Department of Community Health Sciences, at the University of Calgary. Biomarker identification was conducted by the Functional Tissue Imaging Unit at the Tom Baker Cancer Centre Translational Research Laboratory and was funded by the Ohlson Research Initiative. A. J.H. received generous funding from an Alberta Innovates – Health Solutions Clinician Fellowship Award and from the Ohlson Research Initiative. Publisher Copyright: © 2017 Wiley Periodicals, Inc.

PY - 2017/11

Y1 - 2017/11

N2 - Background: The incidence of human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma (SCC) is increasing and has better survival than non-HPV related oropharyngeal SCC. This study compared surgical to nonsurgical treatments and demographic, clinical, and survival differences in patients with oropharyngeal SCC, stratified by p16 status. Methods: We assembled a cohort of adult patients with oropharyngeal SCC diagnosed between 2000 and 2008 in Alberta. The tumor p16 biomarker was measured using fluorescent immunohistochemistry. Results: In this cohort, p16 data were available for 115 of 357 patients; and 66% (n = 76) were p16-positive. Patients with p16 data had comparable outcomes to those without. Surgically treated p16-negative patients had improved 5-year disease-specific survival (DSS) and overall survival (OS) compared with nonsurgical patients. There were no differences in survival outcomes between surgical and nonsurgical treatment for patients with p16-positive disease. Conclusion: Patients with p16-positive oropharyngeal SCC had similar outcomes regardless of treatment. Patients with p16-negative tumors may benefit from primary surgery with postoperative adjuvant therapy.

AB - Background: The incidence of human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma (SCC) is increasing and has better survival than non-HPV related oropharyngeal SCC. This study compared surgical to nonsurgical treatments and demographic, clinical, and survival differences in patients with oropharyngeal SCC, stratified by p16 status. Methods: We assembled a cohort of adult patients with oropharyngeal SCC diagnosed between 2000 and 2008 in Alberta. The tumor p16 biomarker was measured using fluorescent immunohistochemistry. Results: In this cohort, p16 data were available for 115 of 357 patients; and 66% (n = 76) were p16-positive. Patients with p16 data had comparable outcomes to those without. Surgically treated p16-negative patients had improved 5-year disease-specific survival (DSS) and overall survival (OS) compared with nonsurgical patients. There were no differences in survival outcomes between surgical and nonsurgical treatment for patients with p16-positive disease. Conclusion: Patients with p16-positive oropharyngeal SCC had similar outcomes regardless of treatment. Patients with p16-negative tumors may benefit from primary surgery with postoperative adjuvant therapy.

KW - chemoradiation

KW - human papillomavirus

KW - oropharyngeal squamous cell carcinoma

KW - p16

KW - surgery

UR - http://www.scopus.com/inward/record.url?scp=85031676243&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031676243&partnerID=8YFLogxK

U2 - 10.1002/hed.24889

DO - 10.1002/hed.24889

M3 - Article

C2 - 28782304

AN - SCOPUS:85031676243

SN - 1043-3074

VL - 39

SP - 2187

EP - 2199

JO - Head and Neck

JF - Head and Neck

IS - 11

ER -

Primary treatment for oropharyngeal squamous cell carcinoma in Alberta, Canada: A population-based study

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this